Ken Griffin Kymera Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 32,800 shares of KYMR stock, worth $979,080. This represents 0.0% of its overall portfolio holdings.
Number of Shares
32,800
Previous 16,200
102.47%
Holding current value
$979,080
Previous $412,000
219.9%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding KYMR
# of Institutions
164Shares Held
63.1MCall Options Held
39.7KPut Options Held
9.7K-
Price T Rowe Associates Inc Baltimore, MD6.33MShares$189 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$179 Million3.05% of portfolio
-
Atlas Venture Life Science Advisors, LLC5.38MShares$161 Million27.05% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$154 Million6.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.77MShares$142 Million0.0% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $1.63B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...